Clearside Biomedical (CLSD) AI Stock Analysis

• Market Cap: $65.05M
• Dividend Yield: N/A
• Average Volume (3M): 174.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: -79.77%
• EPS Growth: 10.85%
• Country: US
• Employees: 32
• Sector: Healthcare
• Sector Strength: 69
• Industry: Biotechnology
• EPS (TTM): -0.47
• Shares Outstanding: 77,279,290
• 10 Day Avg. Volume: 158,419
• 30 Day Avg. Volume: 174,111
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 9.90
• Price to Cash Flow (P/CF): -3.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.61
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.80
• Price Target Upside: 590.48% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

Clearside Biomedical faces significant financial challenges, with declining revenues and high liabilities outweighing positive clinical trial outcomes and strategic partnerships. The need for additional funding for Phase 3 trials is critical, and while technical indicators suggest potential for a rebound, overall market sentiment remains cautious due to financial instability and operational hurdles.

Positive Factors

Clinical Trial Success

The Phase 2b ODYSSEY trial of CLS-AX in wet AMD reported positive topline results.

FDA Alignment

FDA has approved the proposed phase 3 program for CLS-AX in wAMD, supporting the company's trial design.

Industry Engagement

Clearside Biomedical Inc has participated in key industry conferences, showcasing its commitment to engaging with the healthcare community.

Negative Factors

Financial Stability

The cash available at the end of 2024 provides a financial runway only into the fourth quarter of the following year.

Funding Requirements

The company needs to raise capital to fund the Phase 3 program.

Phase 3 Challenges

The initiation of the phase 3 program is contingent on securing additional financing or entering into a development collaboration.

Clearside Biomedical Business Overview & Revenue Model

Company Description

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

How the Company Makes Money

Clearside Biomedical makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue through licensing agreements, partnerships, and collaborations with other pharmaceutical companies. These partnerships often involve milestone payments, royalties, and sharing of development costs. Additionally, Clearside may earn income from the sale of its proprietary drug candidates once they receive regulatory approval. The company's revenue streams are closely tied to the successful advancement of its pipeline and strategic alliances that facilitate broader market access for its therapies.

Clearside Biomedical Financial Statement Overview

Summary

Clearside Biomedical's financials demonstrate significant challenges, with declining revenues, consistent losses, and a strained balance sheet. The company's reliance on external financing, negative equity, and inability to generate positive cash flows present substantial financial risks.

Income Statement

The company has experienced declining revenue over the years, with total revenue dropping to zero by 2024. This is coupled with persistent negative net income, indicating operational challenges. The absence of revenue growth and consistent losses suggest significant difficulties in generating profit.

Balance Sheet

The company's balance sheet shows a negative stockholders' equity, indicating financial instability. High liabilities relative to assets and negative equity highlight potential solvency concerns. The debt-to-equity ratio is not calculable due to negative equity, but the high total liabilities reflect leverage risks.

Cash Flow

The cash flow statement indicates negative free cash flow and operating cash flow over the years, reflecting challenges in cash generation from operations. Though financing activities provided some relief, reliance on external funding is unsustainable long-term.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	8.23M	1.33M	29.57M	7.89M
	Gross Profit
0.00	7.87M	1.12M	29.40M	7.89M
	EBIT
-28.88M	-24.84M	-30.28M	-627.00K	-17.93M
	EBITDA
-28.88M	-23.06M	-29.46M	-449.00K	-17.93M
	Net Income Common Stockholders
-34.35M	-32.48M	-34.07M	376.00K	-18.03M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.02M	28.92M	48.26M	30.44M	17.29M
	Total Assets
25.13M	34.02M	51.30M	42.90M	19.32M
	Total Debt
703.00K	43.00M	1.28M	675.00K	1.98M
	Net Debt
-19.32M	14.08M	-46.97M	-29.76M	-15.31M
	Total Liabilities
63.98M	49.93M	40.70M	4.93M	10.56M
	Stockholders Equity
-38.85M	-15.91M	10.61M	37.98M	8.76M
Cash Flow		Free Cash Flow
-24.70M	-19.91M	-13.61M	-10.73M	-13.18M
	Operating Cash Flow
-24.70M	-18.14M	-13.37M	-10.73M	-13.12M
	Investing Cash Flow
-638.00K	-1.78M	-246.00K	0.00	-55.00K
	Financing Cash Flow
16.44M	414.00K	31.33M	23.78M	7.87M

Clearside Biomedical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.84
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLSD, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 0.84, below the 50-day MA of 0.90, and below the 200-day MA of 1.04, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 46.99 is Neutral, neither overbought nor oversold. The STOCH value of 49.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLSD.

Clearside Biomedical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
IVVD	44 Neutral	$77.96M	―	-138.71%	―	―	20.91%
ADVM	42 Neutral	$71.35M	―	-144.41%	―	-72.22%	51.40%
CLSD	40 Underperform	$65.05M	―	91.63%	―	-79.77%	10.85%
INZY	39 Underperform	$63.23M	―	-102.90%	―	―	-17.06%
ADAG	38 Underperform	$66.90M	―	-55.14%	―	-99.43%	-69.40%
JSPR	35 Underperform	$71.05M	―	-101.73%	―	―	21.40%

Clearside Biomedical Corporate Events

Clearside Biomedical Reports 2024 Financial Results and Updates

On March 27, 2025, Clearside Biomedical announced its financial results for the fourth quarter and full year 2024, alongside a corporate update. The company reported a decrease in license and other revenue, attributing it to prior year milestone payments, and a net loss increase due to reduced revenue. Clearside highlighted its successful End-of-Phase 2 meeting with the FDA for CLS-AX in wet AMD, and its Asia-Pacific partner’s regulatory progress for ARCATUS® in China. The company also noted multiple collaborations and advancements in its suprachoroidal delivery platform, including Phase 3 plans for diabetic retinopathy and ocular oncology trials, positioning itself for potential pipeline expansion and strategic partnerships.